南非产科与新生儿结局
该研究回顾性审查了2017年7月1日至2018年6月30日南非索韦托、约翰内斯堡内城和开普敦东都市区出生记录,纳入9371名孕妇,估算孕产妇、胎儿和新生儿不良结局发生率,并比较临床记录报告与GAIA病例定义(GAIA-CDs)的吻合度。结果显示妊娠期高血压疾病占14%、早产率26.8%、死产150例(1.6%)等,部分结局因数据缺失导致临床报告与GAIA-CDs吻合度差,作者认为部分GAIA-CDs需修订以提高在中低收入国家的适用性。
要点
- 9371名孕妇中27.6%感染HIV,19.9%在孕早期首次产检,55.3%至少接受1次超声检查。
- 妊娠期高血压疾病14%,妊娠期糖尿病1.3%,早产临产16%,早产儿26.8%,小头畸形5%。
- 死产150例(1.6%);部分GAIA-CDs因数据缺失与临床报告吻合度差。
核心结论
- 该研究为中低收入国家孕产妇及胎儿/新生儿不良结局的背景发生率补充了数据。
- 使用GAIA-CDs有助于数据对齐,但部分GAIA-CDs需修订以提高在中低收入国家的适用性。
研究设计与样本
- 回顾性记录审查,审查2017年7月1日至2018年6月30日南非索韦托、约翰内斯堡内城和开普敦东都市区出生的产科和新生儿病例记录。
- 研究 staff 从随机选取的病历中提取数据至标准化研究表格,共纳入9371名孕妇。
主要发现
- 9371名孕妇中27.6%感染HIV,19.9%在孕早期到产检诊所就诊,55.3%接受≥1次超声检查。
- 14%的孕妇患妊娠期高血压疾病,1.3%患妊娠期糖尿病,16%发生早产临产。
- 死产150例(1.6%),26.8%的婴儿为早产,5%有小头畸形。
- 临床记录中部分不良结局(包括孕产妇和新生儿死亡、重度子痫前期/子痫)的数据能满足所有临床报告病例的GAIA-CDs标准;但满足其他GAIA-CD标准(包括死产、妊娠期糖尿病和妊娠期高血压)所需数据缺失,导致临床报告的不良结局与满足GAIA-CDs的结局之间相关性差。
- 在准确确定孕龄方面也遇到挑战。
关键数值与推荐
- 结局发生率按每10万人口计算,对象为 Brighton Collaboration 和世界卫生组织在疫苗安全性研究中列为优先结局的孕产妇、胎儿和新生儿不良结局。
- 结局发生率通过合并以下病例计算:主治医师在临床记录中报告的病例和/或满足GAIA-CDs的病例。
- 结局报告直接来自临床记录,并与满足GAIA-CDs的结局进行比较。
临床怎么用
- 作者认为使用GAIA-CDs有助于数据对齐,但部分GAIA-CDs需修订以提高在中低收入国家的适用性。
局限性
- 部分GAIA-CD标准(包括死产、妊娠期糖尿病和妊娠期高血压)所需数据缺失,导致临床报告的不良结局与满足GAIA-CDs的结局之间相关性差。
- 在准确确定孕龄方面遇到挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Background epidemiologic population data from low- and middle-income countries (LMIC), on maternal, foetal and neonatal adverse outcomes are limited. We aimed to estimate the incidence of maternal, foetal and neonatal adverse outcomes at South African maternal vaccine trial sites as reported directly in the clinical notes as well as using the 'Global Alignment of Immunization Safety Assessment in Pregnancy' case definitions (GAIA-CDs). GAIA-CDs were utilized as a tool to standardise data collection and outcome assessment, and the applicability and utility of the GAIA-CDs was evaluated in a LMIC observational study. METHODS: We conducted a retrospective record review of maternity and neonatal case records for births that occurred in Soweto, Inner City- Johannesburg and Metro-East Cape Town, South Africa, between 1st July 2017 and 30th June 2018. Study staff abstracted data from randomly selected medical charts onto standardized study-specific forms. Incidence (per 100,000 population) was calculated for adverse maternal, foetal and neonatal outcomes, which were identified as priority outcomes in vaccine safety studies by the Brighton Collaboration and World Health Organization. Outcomes reported directly in the clinical notes and outcomes which fulfilled GAIA-CDs were compared. Incidence of outcomes was calculated by combining cases which were either reported in clinical notes by attending physicians and/ or fulfilled GAIA-CDs. FINDINGS: Of 9371 pregnant women enrolled, 27·6% were HIV-infected, 19·9% attended antenatal clinic in the 1st trimester of pregnancy and 55·3% had ≥1 ultrasound examination. Fourteen percent of women had hypertensive disease of pregnancy, 1·3% had gestational diabetes mellitus and 16% experienced preterm labour. There were 150 stillbirths (1·6%), 26·8% of infants were preterm and five percent had microcephaly. Data available in clinical notes for some adverse outcomes, including maternal- & neonatal death, severe pre-eclampsia/ eclampsia, were able to fulfil GAIA-CDs criteria for all of the clinically-reported cases, however, missing data required to fulfil other GAIA-CD criteria (including stillbirth, gestational diabetes mellitus and gestational hypertension) led to poor correlation between clinically-reported adverse outcomes and outcomes fulfilling GAIA-CDs. Challenges were also encountered in accurately ascertaining gestational age. INTERPRETATION: This study contributes to the expanding body of data on background rates of adverse maternal and foetal/ neonatal outcomes in LMICs. Utilization of GAIA-CDs assists with alignment of data, however, some GAIA-CDs require amendment to improve the applicability in LMICs. FUNDING: This study was funded by Pfizer (Inc).
引用
- Cutland CL, Sawry S, Fairlie L, et al. Obstetric and neonatal outcomes in South Africa. Vaccine. 2024. PMID: 38310014. doi:10.1016/j.vaccine.2024.01.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。